Observational studyBMC oral health2025
Prognostic implications of EBER and EBV DNA combinations in nasopharyngeal carcinoma in endemic areas.
Observational study in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- TLR2 and TLR9 in Brain Cancer Patients in Relation to EBV Status.International journal of molecular sciences · 2026Article
- Epstein-Barr Virus-Mediated Apoptosis Evasion in Epithelial Malignancies: Molecular Mechanisms and Therapeutic Implications.Biology · 2026Review
- Research progress on the mechanisms of EB virus reshaping the immune microenvironment in nasopharyngeal carcinoma.Clinical and experimental medicine · 2026Review
- Application of problem-based learning in EBERs-ISH theoretical and practical teaching.BMC medical education · 2026Article
- Dynamic prognostic nutritional index trajectories predict survival outcomes in nasopharyngeal carcinoma with persistently undetectable plasma Epstein-Barr virus DNA.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEpstein-Barr virus-encoded small RNA (EBER) in situ hybridization is the primary biomarker assay employed to infer Epstein-Barr virus (EBV) involvement in nasopharyngeal carcinoma (NPC). However, discordance between EBER status and EBV DNA detection has been observed in certain NPC patients. This study aims to investigate the prognostic significance of EBER and EBV DNA status.
methodsA total of 2,942 NPC patients with known EBV status, treated at our center between 2016 and 2022, were included in this analysis. Clinical characteristics and survival outcomes were compared between patients who had EBER-negative versus EBER-positive and who were matched in a 1:4 ratio. The Kaplan-Meier method was used to analyze survival data. The association between EBER-EBV DNA status and survival outcomes was assessed using multivariable analysis.
resultsAmong the cohort, 51 patients (1.7%) were EBER-negative, while 2,891 patients (98.3%) were EBER-positive. EBV-negative NPC was significantly associated with the keratinizing subtype (15.7% vs. 0.3%, P < 0.001). EBER-negative patients exhibited a higher propensity for locoregional recurrence compared to their EBER-positive counterparts, with a 5-year locoregional failure-free survival rate of 76.5% (95% CI, 63.3%-92.5%) versus 86.8% (95% CI, 85.0%-88.6%), respectively (P = 0.012). Multivariable analysis further identified a significant association between double-negative status (EBER-/EBV DNA-) and an increased risk of locoregional recurrence (HR: 4.368, 95% CI, 2.058-9.269, P < 0.001), compared to the double-positive one. These associations remained robust after adjustment for confounding factors and in repeated analyses of the matched cohort.
conclusionsThis study highlights the potential prognostic value of EBER and EBV DNA combinations in NPC. However, given the limited number of EBV-negative cases, further investigations are warranted to substantiate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.